3MU3
| Crystal structure of chicken MD-1 complexed with lipid IVa | 分子名称: | (R)-((2R,3S,4R,5R,6R)-3-HYDROXY-2-(HYDROXYMETHYL)-5-((R)-3-HYDROXYTETRADECANAMIDO)-6-(PHOSPHONOOXY)TETRAHYDRO-2H-PYRAN-4-YL) 3-HYDROXYTETRADECANOATE, 2-deoxy-3-O-[(3R)-3-hydroxytetradecanoyl]-2-{[(3R)-3-hydroxytetradecanoyl]amino}-4-O-phosphono-beta-D-glucopyranose, GLYCEROL, ... | 著者 | Yoon, S.I, Hong, M, Han, G.W, Wilson, I.A. | 登録日 | 2010-05-01 | 公開日 | 2010-06-09 | 最終更新日 | 2023-09-06 | 実験手法 | X-RAY DIFFRACTION (2.4 Å) | 主引用文献 | Crystal structure of soluble MD-1 and its interaction with lipid IVa. Proc.Natl.Acad.Sci.USA, 107, 2010
|
|
3MBE
| TCR 21.30 in complex with MHC class II I-Ag7HEL(11-27) | 分子名称: | 2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, MHC CLASS II H2-IAg7 ALPHA CHAIN, ... | 著者 | Corper, A.L, Yoshida, K, Teyton, L, Wilson, I.A. | 登録日 | 2010-03-25 | 公開日 | 2010-05-12 | 最終更新日 | 2023-09-06 | 実験手法 | X-RAY DIFFRACTION (2.886 Å) | 主引用文献 | The diabetogenic mouse MHC class II molecule I-Ag7 is endowed with a switch that modulates TCR affinity. J.Clin.Invest., 120, 2010
|
|
3MJ8
| |
3GAR
| A PH-DEPENDENT STABLIZATION OF AN ACTIVE SITE LOOP OBSERVED FROM LOW AND HIGH PH CRYSTAL STRUCTURES OF MUTANT MONOMERIC GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE | 分子名称: | GLYCINAMIDE RIBONUCLEOTIDE TRANSFORMYLASE, PHOSPHATE ION | 著者 | Su, Y, Yamashita, M.M, Greasley, S.E, Mullen, C.A, Shim, J.H, Jennings, P.A, Benkovic, S.J, Wilson, I.A. | 登録日 | 1998-05-13 | 公開日 | 1998-08-12 | 最終更新日 | 2024-05-22 | 実験手法 | X-RAY DIFFRACTION (1.9 Å) | 主引用文献 | A pH-dependent stabilization of an active site loop observed from low and high pH crystal structures of mutant monomeric glycinamide ribonucleotide transformylase at 1.8 to 1.9 A. J.Mol.Biol., 281, 1998
|
|
6PBV
| Crystal structure of Fab668 complex | 分子名称: | 1,2-ETHANEDIOL, Fab668 heavy chain, Fab668 light chain, ... | 著者 | Oyen, D, Wilson, I.A. | 登録日 | 2019-06-14 | 公開日 | 2020-03-04 | 最終更新日 | 2024-04-03 | 実験手法 | X-RAY DIFFRACTION (1.566 Å) | 主引用文献 | Structure and mechanism of monoclonal antibody binding to the junctional epitope of Plasmodium falciparum circumsporozoite protein. Plos Pathog., 16, 2020
|
|
6Q1Z
| |
6PZD
| |
6PZE
| |
6PZF
| |
6PZG
| Crystal structure of human NA-80 Fab | 分子名称: | NA-80 Fab heavy chain, NA-80 Fab light chain | 著者 | Zhu, X, Wilson, I.A. | 登録日 | 2019-07-31 | 公開日 | 2019-12-04 | 最終更新日 | 2023-10-11 | 実験手法 | X-RAY DIFFRACTION (1.59 Å) | 主引用文献 | Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host Microbe, 26, 2019
|
|
6Q23
| |
6PZH
| Crystal structure of human NA-22 Fab | 分子名称: | NA-22 Fab heavy chain, NA-22 Fab light chain | 著者 | Zhu, X, Wilson, I.A. | 登録日 | 2019-07-31 | 公開日 | 2019-12-04 | 最終更新日 | 2023-10-11 | 実験手法 | X-RAY DIFFRACTION (2.3 Å) | 主引用文献 | Structural Basis of Protection against H7N9 Influenza Virus by Human Anti-N9 Neuraminidase Antibodies. Cell Host Microbe, 26, 2019
|
|
6Q20
| |
5SY8
| |
5T5B
| |
5T29
| Crystal structure of 10E8 Fab light chain mutant3, against the MPER region of the HIV-1 Env, in complex with the MPER epitope scaffold T117v2 | 分子名称: | 10E8 EPITOPE SCAFFOLD T117V2, Antibody 10E8 FAB HEAVY CHAIN, Antibody 10E8 FAB LIGHT CHAIN, ... | 著者 | Irimia, A, Wilson, I.A. | 登録日 | 2016-08-23 | 公開日 | 2017-03-08 | 最終更新日 | 2023-10-04 | 実験手法 | X-RAY DIFFRACTION (2.03 Å) | 主引用文献 | Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog., 13, 2017
|
|
5T3S
| |
5TH0
| |
5THC
| |
5TGO
| |
5T6L
| |
5TFW
| Crystal structure of 10E8 Fab light chain mutant2 against the MPER region of the HIV-1 Env, in complex with T117v2 epitope scaffold | 分子名称: | 1,2-ETHANEDIOL, 10E8 EPITOPE SCAFFOLD T117V2, Antibody 10E8 FAB HEAVY CHAIN, ... | 著者 | Irimia, A, Wilson, I.A. | 登録日 | 2016-09-26 | 公開日 | 2017-03-08 | 最終更新日 | 2023-10-04 | 実験手法 | X-RAY DIFFRACTION (2.168 Å) | 主引用文献 | Lipid interactions and angle of approach to the HIV-1 viral membrane of broadly neutralizing antibody 10E8: Insights for vaccine and therapeutic design. PLoS Pathog., 13, 2017
|
|
5T6N
| |
5T80
| |
5TGU
| |